Target intelligence / Profile preview

Long-chain fatty acid (LCFA)

Target
LCFA
Molecular classification
Other
01

Overview

Long-chain fatty acids are a class of fatty acids with hydrocarbon chains containing 13–21 carbon atoms and a terminal carboxyl group. They comprise both saturated and unsaturated species, are critical constituents of all cells as membrane lipid components, and serve as the body's principal energy stores in adipose tissue. They also give rise to bioactive lipid mediators (e.g., prostaglandins) that participate in inflammation, platelet aggregation, blood pressure regulation, and immune function. Some, such as linoleic acid and alpha-linolenic acid, are essential and must be acquired from the diet. Others, like palmitic acid and stearic acid, are synthesized endogenously. The balance and specific composition of LCFAs in the body strongly influence cardiovascular, metabolic, and inflammatory disease risk.

Other names
LCFAslong-chain saturated fatty acidlong-chain unsaturated fatty acidC13–C21 fatty acidlong-chain polyunsaturated fatty acid (LC-PUFA)
02

Mechanism of action

Not applicable as a drug target. For associated enzymes (e.g., fatty acid synthase, elongases): enzyme inhibition or activation. Omega-3 fatty acids: anti-inflammatory effects, modulation of gene expression (PPAR activation), competition with arachidonic acid for eicosanoid synthesis.

03

Biological functions

Energy storage and metabolic regulationComponent of membrane phospholipids (membrane fluidity and architecture)Precursors for bioactive lipid mediators (eicosanoids, prostaglandins, etc.)Regulation of cell signaling pathways and membrane compartmentalizationSubstrates for β-oxidation (energy production)Immune modulation and inflammation
04

Disease associations

Cardiovascular disease (via dyslipidemia, atherosclerosis)Metabolic diseases: obesity, type 2 diabetes, insulin resistanceInflammationNeurodevelopmental and neurodegenerative disease (for specific LCFAs like DHA and EPA)Other (cancer, autoimmune diseases, liver steatosis)
05

Safety considerations

Dietary excess of saturated LCFAs linked to cardiovascular and metabolic disease riskDeficiency of essential LC-PUFAs (n-3 or n-6) can impair neurodevelopment, immunity, and cardiovascular health
06

Interacting drugs

Omega-3 fatty acid formulations (Eicosapentaenoic acid [EPA], Docosahexaenoic acid [DHA])

2 more in the full profile.

07

Biomarkers

Plasma/serum LCFA composition as a marker of metabolic healthSpecific LCFAs (e.g., EPA/DHA) as biomarkers for cardiovascular or inflammatory disease risk

Beyond the preview

Go deeper on Long-chain fatty acid (LCFA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Long-chain fatty acid (LCFA).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call